argenx Past Earnings Performance
Past criteria checks 3/6
argenx has been growing earnings at an average annual rate of 34.8%, while the Biotechs industry saw earnings growing at 15.2% annually. Revenues have been growing at an average rate of 55.3% per year. argenx's return on equity is 19.4%, and it has net margins of 40.3%.
Key information
34.84%
Earnings growth rate
36.91%
EPS growth rate
Biotechs Industry Growth | 17.04% |
Revenue growth rate | 55.34% |
Return on equity | 19.35% |
Net Margin | 40.26% |
Next Earnings Update | 31 Jul 2025 |
Recent past performance updates
Recent updates
Argenx's CIDP Challenge: A Safety Signal Points To Operational Refinement, Not Ruin
Jun 30Argenx: The Magic May Be Already Priced In
Mar 24argenx: Vyvgart's Sales Momentum Improves, Clinical Data Updates From A Key Competitor Imminent
Feb 27argenx: Lofty Valuation Diminishes Appeal Amid Autoimmune Expansion (Rating Downgrade)
Jan 23Argenx: Strong CIDP Launch, But gMG Growth Propels Q3 Sales Beat
Oct 31argenx: Myositis Data Could Add Billions In Value
Sep 25Argenx: Strong Setup For Outperformance In 2025
Jun 28argenx: Innovation Over Losses In Autoimmune Arena
May 07argenx: Upgrading To 'Strong Buy' On Vyvgart's Q4 Sales, Empasiprubart Data, Pipeline Expansion
Feb 01Argenx files for US approval of subcutaneous form of neuromuscular disorder drug efgartigimod
Sep 21Argenx's neuromuscular disorder drug Vyvgart wins approval in EU
Aug 11Argenx SE GAAP EPS of -$3.81 beats by $0.83, total operating income of $85.18M
Jul 28argenx: A Very Good Start For Vyvgart
May 25argenx SE: Again Following Dutch Biotech, Prior Recommendation Near-Term Gain
May 18argenx SE: Dutch Biotech Has Near Gain Ahead Says Hedging By Market-Makers
Mar 07argenx: Vyvgart's Approval A Key Step For Continued Value Creation
Dec 22argenx SE: Institutional Buying Turnaround In Dutch Biotech With Thin Audience Now Seen As Good Value By Market-Makers
Nov 30argenx: R&D Day Goes Unnoticed
Aug 23argenx: Next Phase Of Growth With Efgartigimod And ARGX-117
Jun 30Revenue & Expenses Breakdown
How argenx makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 25 | 2,643 | 1,064 | 1,096 | 0 |
31 Dec 24 | 2,248 | 833 | 1,055 | 0 |
30 Sep 24 | 1,909 | -40 | 978 | 0 |
30 Jun 24 | 1,660 | -204 | 892 | 0 |
31 Mar 24 | 1,451 | -328 | 799 | 0 |
31 Dec 23 | 1,269 | -295 | 712 | 0 |
30 Sep 23 | 1,029 | -234 | 638 | 0 |
30 Jun 23 | 835 | -397 | 555 | 0 |
31 Mar 23 | 639 | -511 | 520 | 0 |
31 Dec 22 | 441 | -710 | 472 | 0 |
30 Sep 22 | 286 | -909 | 434 | 0 |
30 Jun 22 | 146 | -907 | 407 | 0 |
31 Mar 22 | 381 | -595 | 352 | 0 |
31 Dec 21 | 528 | -408 | 308 | 0 |
30 Sep 21 | 510 | -373 | 270 | 0 |
30 Jun 21 | 526 | -319 | 233 | 0 |
31 Mar 21 | 206 | -573 | 204 | 0 |
31 Dec 20 | 62 | -608 | 172 | 0 |
30 Sep 20 | 75 | -535 | 144 | 0 |
30 Jun 20 | 70 | -359 | 110 | 0 |
31 Mar 20 | 73 | -275 | 86 | 0 |
31 Dec 19 | 93 | -181 | 72 | 0 |
30 Sep 19 | 72 | -109 | 56 | 0 |
30 Jun 19 | 68 | -104 | 49 | 0 |
31 Mar 19 | 70 | -47 | 37 | 0 |
31 Dec 18 | 33 | -76 | 31 | 0 |
30 Sep 18 | 41 | -56 | 27 | 0 |
30 Jun 18 | 44 | -47 | 22 | 0 |
31 Mar 18 | 50 | -46 | 18 | 0 |
31 Dec 17 | 49 | -34 | 15 | 0 |
30 Sep 17 | 42 | -30 | 11 | 0 |
30 Jun 17 | 39 | -25 | 10 | 0 |
31 Mar 17 | 23 | -29 | 10 | 0 |
31 Dec 16 | 18 | -22 | 7 | 0 |
30 Sep 16 | 17 | -20 | 7 | 0 |
30 Jun 16 | 14 | -17 | 6 | 0 |
31 Mar 16 | 12 | -17 | 6 | 0 |
31 Dec 15 | 11 | -17 | 5 | 0 |
30 Sep 15 | 10 | -16 | 5 | 0 |
30 Jun 15 | 9 | -14 | 5 | 0 |
31 Mar 15 | 7 | -12 | 4 | 0 |
31 Dec 14 | 7 | -12 | 4 | 0 |
30 Sep 14 | 6 | -10 | 4 | 0 |
Quality Earnings: ARGX has high quality earnings.
Growing Profit Margin: ARGX became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ARGX has become profitable over the past 5 years, growing earnings by 34.8% per year.
Accelerating Growth: ARGX has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: ARGX has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (21.7%).
Return on Equity
High ROE: ARGX's Return on Equity (19.4%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/07/23 21:29 |
End of Day Share Price | 2025/07/23 00:00 |
Earnings | 2025/03/31 |
Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
argenx SE is covered by 50 analysts. 29 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Joel Beatty | Baird |
Charles Pitman | Barclays |
Richard Parkes | BNP Paribas Exane |